ReviewProblemy endokrinologii2026
[The relationship between Parkinson's disease and metabolic disorders: the impact of systemic dysfunctions on neurodegeneration].
Review in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines the association between Parkinson's disease (PD) and diabetes, two global epidemics closely linked to aging. The analysis is based on recent epidemiological data indicating that diabetes significantly increases the risk of developing PD and exacerbates its progression, affecting both motor and cognitive functions. The paper explores shared pathophysiological mechanisms, including impaired insulin signaling, insulin resistance, oxidative stress, mitochondrial dysfunction, chronic inflammation and neuroinflammation, dysregulated glucose metabolism, and gut microbiota dysbiosis. These interconnected processes create a vicious cycle in which each pathology reinforces the others, driving neurodegeneration, particularly in vulnerable dopaminergic neurons of the substantia nigra. The uniqueness of this review lies in the integration of current research, providing a dual-perspective approach to comorbidity - addressing both neurodegenerative and metabolic dysfunctions. Understanding these shared mechanisms opens avenues for developing multi-targeted therapeutic strategies, including dietary interventions, lifestyle modifications, and gut microbiota modulation. This approach distinguishes the present review from similar works by offering a comprehensive perspective on the issue and emphasizing the need for further studies to identify precise biomarkers and develop effective disease-modifying treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.